uniQure to Participate in Multiple Upcoming Industry Conferences in September
August 30 2019 - 7:00AM
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced that it will participate in the following
upcoming conferences in September:
- Citi 14th Annual Biotech
Conference, September 4 – 5, Boston,
MA.• Matt Kapusta, chief executive
officer at uniQure, and Sander van Deventer, M.D., Ph.D.,
executive vice president research and product development, will
attend and participate in investor meetings at the conference on
Wednesday September 4.• Mr. Kapusta also will participate in the
panel discussion “Peering Into the Gene Therapy Crystal Ball - What
Does the Future Look Like?” that same day at 10:15 a.m. ET. The
live webcast of the panel discussion can be accessed through the
link displayed in the Investor section of the uniQure website. The
webcast replay will be available for at least 72 hours following
the live event.
- Wells Fargo 2019 Healthcare Conference, September 4 –
5, Boston, MA. • Matt Kapusta and Sander van
Deventer will attend and participate in investor meetings at the
conference on Thursday, September 5.• Mr. Kapusta also will present
a corporate update on Thursday, September 5, at 10:20 a.m.
ET. The live webcast of the corporate update can be
accessed through the link displayed in the Investor section of the
uniQure website. The webcast replay will be available for at least
72 hours following the live event.
- Morgan Stanley 17th Annual Global Healthcare
Conference, September 9 – 11, New York City.• Matt
Kapusta will host investor meetings at the conference on Monday,
September 9, and also participate in a fireside chat at 8:10 a.m.
ET. The live webcast of the panel discussion can be accessed
through the link displayed in the Investor section of the uniQure
website. The webcast replay will be available for at least 72 hours
following the live event.
- National Hemophilia
Foundation (NHF) 15th Workshop on Novel Technologies and Gene
Transfer for Hemophilia, September 13 – 14, Washington,
DC.• On Friday, September 13 at 9:15
a.m. ET, Eileen Sawyer, Ph.D., vice president of medical affairs,
will present “Recent Progress in the Development Program of AMT-061
for Persons with Severe or Moderately Severe Hemophilia B.”• At
2:00 p.m. ET on Friday, September 13, Sander van Deventer will
present “Overcoming pre-existing immunity”.
- The 5th Animal Models of
Neurodegenerative Diseases, September 15 – 18, Chateau Liblice,
CZ.• On Monday September 16, Melvin Evers, Ph.D.,
associate director research at uniQure, will present “The
development of microRNA-based gene therapy for Huntington’s
disease.”• Astrid Valles-Sanchez, Ph.D., senior scientist at
uniQure, will present “Translational efficacy measures of
huntingtin lowering in small and large animal models of
Huntington’s disease” on Tuesday September 17.
- International Congress of Parkinson’s Disease and
Movement Disorders – MDS 2019, September 22 -26, 2019, Nice,
FR. • uniQure will deliver the following
presentations on the development of AMT-130 for Huntington’s
disease during the conference:
- Title: MRI,
Clinical, and Neuropathological Findings after Bilateral
Intra-striatal Administration of rAAV5-miHTT in Non-human
PrimatesAbstract number: 18Presentation
Date: Monday, September 23Presentation
time: 1:45 – 3:15 p.m. CET
- Title: Translating
Preclinical Data to a Human Equivalent Dose for AMT-130 AAV Gene
Therapy for Early Manifest Huntington’s Disease
PatientsAbstract number: 14Presentation
Date: Monday, September 23Presentation
time: 1:45 – 3:15 p.m. CET
- Title: Sustained
Mutant Huntingtin Lowering in the Brain and Cerebrospinal Fluid of
Huntington’s Disease Minipigs Mediated by AAV5-miHTT Gene
TherapyAbstract number: 53Presentation
Date: Monday, September 23Presentation
time: 1:45 – 3:15 p.m. CET
- Title: Exploring
the Effects of Intrastriatal AAV5-miHTT Lowering Therapy on MRS
Signal and Mutant Huntingtin Levels in the Q175FDN Mouse Model of
Huntington’s DiseaseAbstract number:
25Presentation date: Monday, September
23Presentation time: 1:45 – 3:15 p.m. CET
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary gene therapies to treat patients with hemophilia B,
hemophilia A, Huntington's disease, Fabry disease, spinocerebellar
ataxia Type 3 and other diseases. www.uniQure.com
uniQure Contacts: |
|
|
|
|
|
FOR INVESTORS: |
|
FOR MEDIA: |
|
|
|
Maria E. Cantor |
Eva M. Mulder |
Tom Malone |
Direct: 339-970-7536 |
Direct: +31 20 240 6103 |
Direct: 339-970-7558 |
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Aug 2024 to Sep 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Sep 2023 to Sep 2024